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Background: We recently reported that short-term treatment with liraglutide (20.0 ± 6.4 days) reduced body weight
and improved some scales of eating behavior in Japanese type 2 diabetes inpatients. However, it remained
uncertain whether such liraglutide-induced improvement is maintained after discharge from the hospital. The aim
of the present study was to determine the long-term effects of liraglutide on body weight, glycemic control, and
eating behavior in Japanese obese type 2 diabetics.
Methods: Patients with obesity (body mass index (BMI) >25 kg/m2) and type 2 diabetes were hospitalized at Osaka
University Hospital between November 2010 and December 2011. BMI and glycated hemoglobin (HbA1c) were
examined on admission, at discharge and at 1, 3, and 6 months after discharge. For the liraglutide group (BMI;
31.3 ± 5.3 kg/m2, n = 29), patients were introduced to liraglutide after correction of hyperglycemic by insulin or oral
glucose-lowering drugs and maintained on liraglutide after discharge. Eating behavior was assessed in patients
treated with liraglutide using The Guideline For Obesity questionnaire issued by the Japan Society for the Study of
Obesity, at admission, discharge, 3 and 6 months after discharge. For the insulin group (BMI; 29.1 ± 3.0 kg/m2,
n = 28), each patient was treated with insulin during hospitalization and glycemic control maintained by insulin
after discharge.
Results: Liraglutide induced significant and persistent weight loss from admission up to 6 months after discharge,
while no change in body weight after discharge was noted in the insulin group. Liraglutide produced significant
improvements in all major scores of eating behavior questionnaire items and such effect was maintained at
6 months after discharge. Weight loss correlated significantly with the decrease in scores for recognition of weight
and constitution, sense of hunger, and eating style.
Conclusion: Liraglutide produced meaningful long-term weight loss and significantly improved eating behavior in
obese Japanese patients with type 2 diabetes.
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The worldwide epidemic of type 2 diabetes has been
fueled by the increase in the number of obese and over-
weight people. Similar to Western countries, in East
Asian countries, the risk of death from cancer and car-
diovascular diseases has increased in parallel with the in-
crease in body mass index (BMI) [1]. The World Health
Organization (WHO) estimates that 2.3 billion adults
will be overweight and >700 million will be obese by
2015 [2]. Effective therapeutic strategy for obese type 2
diabetes should be developed without delay, but it is
often difficult to control appetite and to maintain body
weight in obese type 2 diabetes patients. Intensive insu-
lin therapy may result in fine glycemic control and pre-
vent microvascular complications, but such treatment
usually increases body weight [3]. In addition, the oral
glucose-lowering agents sulfonylurea (SU) and thiazoli-
dinedione also increase body weight by enhancing glu-
cose uptake into adipocytes.
Liraglutide, a glucagon-like peptide (GLP-1) analogue,
is a member of new classes of anti-diabetic agents and is
characterized by induction of insulin secretion only dur-
ing hyperglycemia as an incretin effect. The Liraglutide
Effect and Action in Diabetes (LEAD) studies have
demonstrated a significant weight reduction by liraglu-
tide [4], but such liraglutide-mediated weight reduction
has not been observed in Japanese type 2 diabetes
patients [5-7]. Subjects of the LEAD trial were obese
type 2 diabetic patients, while the Japanese subjects en-
rolled in the liraglutide trial were non-obese type 2 dia-
betes patients (BMI; 23.5-25 kg/m2). In a pilot study, we
recently reported that short-term liraglutide treatment
reduced BMI, waist circumference, and visceral fat area,
and reduced the scale for eating behavior in Japanese
type 2 diabetes inpatients (age; 61.2 ± 14.0 years, BMI;
28.3 ± 5.2 kg/m2, duration of diabetes; 16.9 ± 6.6 years)
[8]. However, this short-term study was performed only
during hospitalization and thus it remains uncertain
whether these effects of liraglutide are maintained after
discharge. In the present study, we investigated the effect
of liraglutide on body weight, glycemic control, and eat-
ing behavior until 6 months after discharge in Japanese
obese patients (BMI >25 kg/m2) with type 2 diabetes.
Materials and methods
Subjects and clinical examination
The study subjects were selected among patients hospi-
talized at the Division of Endocrinology and Metabolism
of Osaka University Hospital between November 2010
and December 2011. All patients were hospitalized to
undergo medical treatment for diabetes. The inclusion
criteria were as follows: (1) type 2 diabetes with obesity
(BMI >25 kg/m2) at admission; (2) patients continued to
visit Osaka University Hospital for treatment afterdischarge; (3) patients were treated with liraglutide or
insulin at discharge and continued to be treated with the
same regimen after discharge. Physical examination and
various metabolic parameters were measured on admis-
sion. Body weight and HbA1c were examined at 1, 3,
and 6 months after discharge. The selection of the
glucose-lowering agent for treatment was left to the
attending physician. In the liraglutide group, each pa-
tient was treated with insulin or oral glucose-lowering
drugs under diet therapy after admission. After achieving
the target levels of glycemic control [fasting plasma glu-
cose (FPG) <150 mg/dL and postprandial 2-h plasma
glucose <200 mg/dL], treatment with insulin or oral
glucose-lowering agents was replaced with liraglutide at
0.3 mg/day, which was increased by 0.3 mg/day every
one week to a final dose of 0.9 mg/day, representing the
maximum dose used in Japan. The introduction of lira-
glutide and increase in liraglutide dosage was decided by
the attending physician. In the insulin group, each pa-
tient was treated with insulin during hospitalization and
glycemic control was maintained by insulin treatment
after discharge.
Written consent was obtained from each subject after
explaining the purpose and possible complications of the
study. The study protocol was approved by the human
ethics committee of Osaka University and was registered
with the University hospital Medical Information Net-
work (Number: UMIN 000004192).
Questionnaire for eating behavior
Eating behavior was assessed in patients on liraglutide
treatment by using the questionnaire of The Guideline
For Obesity issued by the Japan Society for the Study of
Obesity, at admission, discharge, 3 and 6 months after
discharge. As reported previously [8], this questionnaire
consists of 55-item questions of seven major scales as
follows: 1) Recognition for weight and constitution (e.g.,
‘Do you think it is easier for you to gain weight than
others?’), 2) External eating behavior (e.g., ‘If food smells
and looks good, do you eat more than usual?’), 3) Emo-
tional eating behavior (e.g., ‘Do you have the desire to
eat when you are irritated?’), 4) Sense of hunger (e.g. ‘Do
you get irritated when you feel hungry?’), 5) Eating style
(e.g., ‘Do you eat fast?’), 6) Food preference (e.g., ‘Do you
like meat?’), 7) Regularity of eating habits (e.g., ‘Is your
dinner time too late at night?’). All items were rated on
a four-point scale ranging from 1 (seldom) to 4 (very
often).
Statistical analysis
The Student's t-test and χ2 test were used to compare
baseline characteristics of the liraglutide and insulin
groups. Variables with skewed distribution were analyzed
by the Mann–Whitney U-test. The Student's t-test was
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discharge, and post-discharge. In all cases, P values
<0.05 were considered statistically significant. All ana-
lyses were performed using the JMP software (JMP 8.0;
SAS Institute Inc., Cary, NC).
Results
Characteristics of participants
Table 1 shows the baseline characteristics of 29 sub-
jects on liraglutide and 28 subjects on insulin treat-
ment. For the liraglutide group, the mean BMI was
31.3 kg/m2, glycated hemoglobin (HbA1c) was 8.5%,
and fasting C-peptide was 2.09 ng/mL. Among the
patients of the liraglutide group, 55% were treated with
insulin at admission. The baseline characteristics of
patients of the insulin group were similar to those of
the liraglutide group, but HbA1c levels and frequencies
of insulin treatment before admission were higher in
the insulin group compared to the liraglutide group.
The duration of diabetes and fasting C-peptide level
were similar in both groups. Thus, the enrolled
patients were obese Japanese subjects, had relatively
long duration of diabetes, and most of them were trea-
ted with insulin, but had preserved insulin secretion
capacity.Table 1 Baseline characteristics
Liraglutide
Males/females 12/17
Age (years) 58.1 ± 12.1
Duration of diabetes (years) 16.0 ± 8.3
Body weight (kg) 82.0 ± 16.2
Body mass index (kg/m2) 31.3 ± 5.3
HbA1c (%) 8.5 ± 1.4
Fasting plasma glucose (mg/dL) 159.0 ± 49.7
Fasting C-peptide (mg/dL) 2.09 ± 0.97
Low-density lipoprotein-cholesterol (mg/dL) 113.1 ± 36.5
High-density lipoprotein-cholesterol (mg/dL) 44.2 ± 8.1






Alpha-glucosidase inhibitor (%) 17
Thiazolidinedione (%) 21
DPP-IV inhibitor (%) 10
Glinide (%) 3
Insulin (%) 55
Data are mean ± SD or number of subjects.The number of patients treated at discharge with lira-
glutide at 0.3, 0.6, and 0.9 mg/day was 3, 11, and 15
patients, respectively. The total daily dose (TDD) of in-
sulin was 0.59 unit/kg/day at discharge in the insulin
group. In the liraglutide group, the duration of
hospitalization was 30.8 ± 9.3 days and the time from lir-
aglutide induction to discharge was 20.0 ± 6.9 days. In
the insulin group, the duration of hospitalization was
29.1 ± 8.4 days, indicating similar duration of
hospitalization in the two groups. At 6 month after dis-
charge, the number of patients treated with liraglutide at
0.3, 0.6, and 0.9 mg/day was 3, 7, and 19 patients, and
SU and biguanide was used in 10 and 15 patients of the
liraglutide group, respectively. In the insulin group, SU,
biguanide, and alpha-glucosidase inhibitor was used by
1, 9, and 3 patients at 6 month after discharge, respect-
ively. There were no differences in the frequency of
hypoglycemic episode between the liraglutide and insulin
groups.
Changes in body weight and HbA1c
Body weight and HbA1c were measured during
hospitalization and after discharge. In the liraglutide
group, BMI at admission, discharge, 1, 3, and 6 months
after discharge were 31.3 ± 5.3, 29.3 ± 4.8, 28.8 ± 4.6,(n = 29) Insulin (n = 28) P value
14/14 0.514
63.9 ± 12.2 0.080
18.5 ± 10.0 0.309
76.6 ± 15.5 0.122
29.1 ± 3.0 0.102
9.4 ± 1.6 0.023
156.4 ± 59.2 0.655
1.97 ± 0.24 0.267
116.6 ± 28.2 0.689
46.1 ± 13.8 0.534
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treatment significantly decreased BMI even after
6 months from discharge compared to admission
(P < 0.001). Figure 1A shows changes in body weight
from admission in both groups. In the insulin group,
body weight was significantly reduced from admission to
discharge while there were no changes in body weight
from discharge to 6 months (Figure 1A). Changes in
body weight at 1, 3, and 6 months after discharge were
significantly larger in the liraglutide group than in the
insulin group after adjustment for age, sex, BMI, HbA1c,
and insulin treatment at admission (P < 0.001). Among
the subjects treated with liraglutide, the change in body
weight at 6 months after discharge correlated signifi-
cantly with BMI at admission (P= 0.002).
HbA1c was significantly reduced at 1 month from dis-
charge but tended to increase at 6 months after dis-
charge in both groups (Figure 1B). Liraglutide treatment
significantly reduced the mean HbA1c by −1.1% at























Figure 1 Serial changes in body weight (A) and HbA1c (B)
induced by insulin and liraglutide. Data are mean± SEM. Adm,
admission; Dis, discharge; Mo, month. ***P< 0.001, compared with
the values at discharge. †† P< 0.01, ††† P< 0.001, compared with
the values of the insulin group. }} P< 0.01, }}} P< 0.001, compared
with the values at admission.administration also significantly decreased HbA1c, and
the reduction in HbA1c was similar in both liraglutide
and insulin group. After adjustment for age, sex, BMI,
HbA1c, and insulin treatment at admission, the decrease
in HbA1c was significant only at 1 month after discharge
in the liraglutide group compared with the insulin group
(P < 0.05).
Assessment of eating behavior
Next, the effect of liraglutide on eating behavior was
evaluated in 16 subjects (8 males and 8 females) until
6 months after discharge. Figure 2 depicts the scores of
the questionnaire for eating behavior at admission, dis-
charge, 3 months, and 6 months after discharge. The
scores for recognition of weight and constitution
(Figure 2A) and external eating behavior (Figure 2B)
were not changed at discharge, but were significantly
decreased at 3 and 6 months after discharge. Emotional
eating behavior was reduced at 3 month after discharge
but tended to deteriorate at 6 month after discharge
(Figure 2C). Importantly, liraglutide treatment promptly
reduced the score for sense of hunger and markedly sup-
pressed the sense of hunger (Figure 2D). The score for
eating style decreased gradually and was significantly
reduced at 3 and 6 months after discharge (Figure 2E).
Interestingly, the score for food preference (Figure 2F),
especially requirement for fat (Figure 2G), was signifi-
cantly decreased by liraglutide at 3 and 6 months after
discharge. Liraglutide treatment reasonably reduced the
score for regularity of eating habit at discharge and
maintained the same reduction until 6 months after dis-
charge (Figure 2H).
Next, we examined the correlations between changes
in body weight and eating behavior from admission to
6 months after discharge. The decrease in total score of
eating behavior correlated significantly with the extent of
weight loss (P= 0.029, R = 0.48). Interestingly, weight loss
correlated significantly with the decrease in the scores
for recognition of weight and constitution (P= 0.007,
R = 0.57), sense of hunger (P= 0.021, R = 0.50), and eating
style (P= 0.037, R = 0.46). The decrease in the score for
external eating behavior tended to be associated with
weight reduction (P= 0.061, R = 0.42). The scales for
other parameters of eating behavior did not correlate sig-
nificantly with weight reduction.
Figure 3 shows a radar chart of the eating behavior.
The black dotted line represents the scores of non-obese
healthy subjects. All scales for eating behavior were dis-
ordered at admission (red line), but these parameters
tended to show improvement at discharge (yellow line).
Furthermore, all scales showed further improvement and
the scores of eating behavior moved towards those of
the non-obese healthy subjects at 3 (green line) and 6







































































































































































Figure 2 Changes in the scores of eating behavior induced by
liraglutide. Eating behavior was assessed in 16 patients (8 males
and 8 females) using a questionnaire as described in the Methods
section. Data are mean± SEM. *P< 0.05, **P< 0.01, compared with
the values at admission.
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The major findings of the present study were: 1) liraglu-
tide treatment effectively reduced body weight up to
6 months after discharge compared to conventional in-
sulin therapy in Japanese obese patients with type 2diabetes; 2) liraglutide-induced reduction in HbA1c was
similar to that observed with insulin treatment; 3) main-
tained improvement in eating behavior up to 6 months
after discharge in patients on liraglutide treatment with
various scales gradually moving to those recorded in
non-obese normal subjects.
The LEAD-5 study demonstrated that liraglutide
decreased HbA1c similar to ultra-long acting insulin
analogue, glargine, and also significantly reduced body
weight compared with glargine [9]. In the present retro-
spective study, we compared the effects of liraglutide
and insulin on body weight and HbA1c. Almost all
patients of the insulin group received intensive insulin
therapy at discharge, and the TDD of insulin was rela-
tively high (0.59 unit/kg/day). Significant body weight re-
duction was observed in both liraglutide and insulin
groups during hospitalization and this was due to the in-
hospital diet therapy. However, weight reduction was
persistently observed after discharge only in the liraglu-
tide group. Liraglutide treatment may be distinguished
from the intensive insulin therapy by effective reductions
in body weight and HbA1c. Further studies are needed
to determine the differences in the therapeutic effects of
liraglutide and intensive insulin therapy. The combin-
ation treatment of GLP-1 receptor agonist and basal in-
sulin has been also approved in the USA and EU [10],
but is yet to be approved in Japan. The effect of such
combination therapy on body weight needs to be exam-
ined in the future.
GLP-1 promotes satiety and reduces food intake
[11,12], but the effect of GLP-1 treatment on eating be-
havior has not been fully examined in human subjects
with type 2 diabetes. We reported recently that short-
term treatment with liraglutide did not only reduce food
intake and visceral fat adiposity but also decreased the
scores of certain parameters of eating behavior during
hospitalization [8]. However, we did not provide evi-
dence for the long-term effects of liraglutide on eating
behavior. Interestingly, the scores of obese type 2 dia-
betic patients at admission were higher in all major
scales than non-obese subjects (Figure 3). Liraglutide ad-
ministration decreased these scores and maintained such
improvement in eating behavior, with the exception of
the scale of emotional eating behavior, until 6 months
after discharge, and the total score of eating behavior of
some liraglutide-treated patients moved closer to that of
non-obese healthy subjects. GLP-1 delays gastric empty-
ing and induces satiety, which is probably related to the
combined effect of GLP-1 on the gastrointestinal tract
and the brain, leading to decreased energy intake and
weight reduction [13,14]. Furthermore, the improvement
in the scale for eating style by liraglutide may be partly
accounted for by GLP-1-induced suppression of gastro-






Figure 3 Liraglutide-induced improvement in eating behavior. Changes in the scores of eating behavior were expressed as a radar chart.
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the reduction in the scores for sense of hunger and eat-
ing style, suggesting that the liraglutide-induced weight
reduction is mediated partly through improvement in
eating behavior.
A recent meta-analysis of weight reduction by GLP-1
receptor agonists showed that administration of these
agents resulted in 3% weight reduction at 6 months [15].
The LEAD-5 trial showed 2.1% weight reduction under
treatment with liraglutide at 1.8 mg/day [9]. Further, an-
other study, which used liraglutide at up to 3.0 mg/day
for 20 weeks for treatment of obesity (BMI; 30–40 kg/
m2), reported 7.4% weight loss [16]. In present study, lir-
aglutide administered at the maximum dose of 0.9 mg/
day achieved about 10% body weight reduction at
6 months after discharge. This result far exceeds those
of previous studies [9,15,16]. What are the reasons for
the excellent results noted in the present study? 1)
Patients treated with liraglutide were also placed on
strict diet therapy and received a special educational
program for weight reduction during hospitalization
over 30.8 ± 9.3 days. The importance of these two factors
is evident from the rate of weight reduction in the lira-
glutide group achieved in the present study; weight re-
duction of −6.5% during hospitalization and only −3.5%
between discharge and 6 months after discharge. 2) It is
possible that GLP-1 analogue exhibited its utmost effect-
iveness on weight reduction, because glucose toxicity
was corrected mainly by insulin therapy before induction
of liraglutide. A poor response to GLP-1 has been
described in patients with poorly controlled diabetes but
this is reversed following normalization of glycemic con-
trol [17,18]. High levels of serum GLP-1 were also
reported in patients with the metabolic syndrome [19],suggesting the existence of “GLP-1 resistance”. Our
group has also demonstrated low expression levels of
GLP-1 receptor mRNA in the islets of obese mice, which
were significantly reversed after glucose-lowering medi-
cations [20].
GLP-1 receptor agonists do not only have glucose-
lowering effect but also improve other metabolic para-
meters such as lipid profile and blood pressure following
5-10% weight reduction [21]. Long-term treatment with
exenatide, a GLP-1 receptor agonist, significantly
improved cardiovascular risk factors, such as LDL-C,
HDL-C, and triglyceride, and biomarkers of liver func-
tion [22]. Furthermore, treatment with GLP-1 improved
postprandial hyperlipidemia, suggesting that GLP-1
could reduce cardiovascular disease risk in type 2 dia-
betes [23]. In present study, liraglutide significantly
decreased LDL-C at 6 months after discharge (admis-
sion: 113.1 ± 36.5, at 6 months after discharge:
95.3 ± 22.9 mg/dL, P =0.03) although 66% of the patients
were treated with statins at admission. As shown in
Figure 2G, the score for requirement for fat decreased
after liraglutide, suggesting that reduction of dietary fat
intake partly contributed to the observed decrease in
LDL-C. However, the questionnaire did not contain
questions about the types of fat consumed, e.g. saturated
fat or non-saturated fat, and daily frequency or quantity
of fat intake. Questions for food preference would be
further improved in the future. Several studies have
described the extrapancreatic actions of GLP-1, espe-
cially its beneficial effects on the cardiovascular system
[2]. Treatment with GLP-1 improved endothelial dys-
function in type 2 diabetics with ischemic heart diseases
[24]. We recently showed that short-term liraglutide
treatment decreased serum high-sensitivity C-reactive
Fujishima et al. Cardiovascular Diabetology 2012, 11:107 Page 7 of 8
http://www.cardiab.com/content/11/1/107protein (hsCRP) and soluble intracellular adhesion
molecule-1 (sICAM-1) levels [8]. Long-term prospective
studies are needed to determine whether the observed
changes in obesity, eating behavior, and various meta-
bolic parameters induced by treatment with liraglutide
translate into protection against cardiovascular events in
obese type 2 diabetics.
The present study has several limitations. The study
was not a randomized clinical trial (RCT) and not pro-
spective in design. The baseline characteristics of the
patients of the liraglutide and insulin groups were not
identical. In addition, the present study included a rela-
tively small population. Furthermore, assessment of eat-
ing behavior could not been performed in the insulin
group.
In summary, treatment with liraglutide effectively
reduced body weight and improved eating behavior in
obese Japanese patients with type 2 diabetes for up to
6 months. Liraglutide is potentially useful for the treat-
ment of obese patients with type 2 diabetes. The weight-
lowering effects of liraglutide should be examined in
more detail in the future in a double-blind placebo-con-
trolled clinical trial.
Competing interests
The authors declare no competing interests.
Authors’ contributions
YF acquired and analyzed data, and wrote the manuscript. NM conceived
study, analyzed data, and wrote the manuscript. KI, SK, HN, AM, JK, TY, KO,
and AI acquired and researched data. TF and IS reviewed the manuscript. All
authors read and approved the final manuscript.
Acknowledgments
We thank Miyuki Nakamura from the Department of Metabolic Medicine,
Graduate School of Medicine, Osaka University, for the excellent technical
assistance. This work was supported in part by Grants-in-Aid for Scientific
Research (C) no. 22590979 (to N. M.) and Scientific Research on Innovative
Areas no. 22126008 (to T. F.).
Received: 13 July 2012 Accepted: 7 September 2012
Published: 14 September 2012
References
1. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, He J, Gupta
PC, Ramadas K, Tsugane S, Irie F, Tamakoshi A, Gao YT, Wang R, Shu XO,
Tsuji I, Kuriyama S, Tanaka H, Satoh H, Chen CJ, Yuan JM, Yoo KY, Ahsan H,
Pan WH, Gu D, Pednekar MS, Sauvaget C, Sasazuki S, Sairenchi T, Yang G,
Xiang YB, Nagai M, Suzuki T, Nishino Y, You SL, Koh WP, Park SK, Chen Y,
Shen CY, Thornquist M, Feng Z, Kang D, Boffetta P, Potter JD: Association
between body-mass index and risk of death in more than 1 million
Asians. N Engl J Med 2011, 364:719–729.
2. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M: Cardiovascular
comorbidities of type 2 diabetes mellitus: defining the potential of
glucagon like peptide-1-based therapies. Am J Med 2011, 124:S35–S53.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998, 352:837–853.
4. Blonde L, Russell-Jones D: The safety and efficacy of liraglutide with or
without oral antidiabetic drug therapy in type 2 diabetes: an overview
of the LEAD 1–5 studies. Diabetes Obes Metab 2009, Suppl 3:26–34.
5. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K: Dose-dependent
improvement in glycemia with once-daily liraglutide withouthypoglycemia or weight gain: A double-blind, randomized, controlled
trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract
2008, 81:161–168.
6. Seino Y, Rasmussen MF, Nishida T, Kaku K: Efficacy and safety of the once-
daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy
in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010,
26:1013–1022.
7. Kaku K, Rasmussen MF, Clauson P, Seino Y: Improved glycaemic control
with minimal hypoglycaemia and no weight change with the once-daily
human glucagon-like peptide-1 analogue liraglutide as add-on to
sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes
Metab 2010, 12:341–347.
8. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita
K, Imagawa A, Funahashi T, Shimomura I: Short-term effects of liraglutide
on visceral fat adiposity, appetite, and food preference: a pilot study of
obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 2011,
10:109.
9. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M,
Ravn GM, Simó R: Liraglutide Effect and Action in Diabetes 5 (LEAD-5)
met + SU Study Group. Diabetologia 2009, 52:2046–2055.
10. Berlie H, Hurren KM, Pinelli NR: Glucagon-like peptide-1 receptor agonists
as add-on therapy to basal insulin in patients with type 2 diabetes: a
systematic review. Diabetes Metab Syndr Obes 2012, 5:165–174.
11. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB:
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body
weight and food intake in obese candy-fed rats, whereas a dipeptidyl
peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8–15.
12. Raun K, von Voss P, Knudsen LB: Liraglutide, a once-daily human
glucagon-like peptide-1 analog, minimizes food intake in severely obese
minipigs. Obesity 2007, 15:1710–1716.
13. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D:
Clinical review: The extrapancreatic effects of glucagon-like peptide-1
and related peptides. J Clin Endocrinol Metab 2009, 94:1843–1852.
14. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C,
Doran S, Jax T, Zdravkovic M, Chapman IM: Effect of the once-daily human
GLP-1 analogue liraglutide on appetite, energy intake, energy
expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin
Pract 2012, 97:258–266.
15. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E: Effects of
glucagon-like peptide-1 receptor agonists on body weight: a meta-
analysis. Exp Diabetes Res 2012, 2012:672658.
16. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M,
Madsen J, Rasmussen MF, Lean ME: NN8022-1807 Study Group: Effects of
liraglutide in the treatment of obesity: a randomised, double-blind,
placebo-controlled study. Lancet 2009, 374:1606–1616.
17. Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ,
Madsbad S: Near normalisation of blood glucose improves the
potentiating effect of GLP-1 on glucose-induced insulin secretion in
patients with type 2 diabetes. Diabetologia 2008, 51:632–640.
18. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ,
Madsbad S: Four weeks of near-normalisation of blood glucose improves
the insulin response to glucagon-like peptide-1 and glucose-dependent
insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia
2009, 52:199–207.
19. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T,
Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like
peptide-1, are associated with metabolic components in high-risk
patients with cardiovascular disease. Cardiovasc Diabetol 2010, 9:17.
20. Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K,
Yamamoto T, Matsuhisa M, Shimomura I: Effect of alogliptin, pioglitazone
and glargine on pancreatic β-cells in diabetic db/db mice. Biochem
Biophys Res Commun 2011, 404:534–540.
21. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO,
Brancati FL, Peters A, Wagenknecht L: Look AHEAD Research Group:
Benefits of modest weight loss in improving cardiovascular risk factors
in overweight and obese individuals with type 2 diabetes. Diabetes Care
2011, 34:1481–1486.
22. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle
ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk
factors and hepatic biomarkers in patients with type 2 diabetes treated
for at least 3 years. Curr Med Res Opin 2008, 24:275–286.
Fujishima et al. Cardiovascular Diabetology 2012, 11:107 Page 8 of 8
http://www.cardiab.com/content/11/1/10723. Ansar S, Koska J, Reaven PD: Postprandial hyperlipidemia, endothelial
dysfunction and cardiovascular risk: focus on incretins. Cardiovasc
Diabetol 2011, 10:61.
24. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A:
Effects of glucagon-like peptide-1 on endothelial function in type 2
diabetes patients with stable coronary artery disease. Am J Physiol
Endocrinol Metab 2004, 287:E1209–E1215.
doi:10.1186/1475-2840-11-107
Cite this article as: Fujishima et al.: Efficacy of liraglutide, a glucagon-like
peptide-1 (GLP-1) analogue, on body weight, eating behavior, and
glycemic control, in Japanese obese type 2 diabetes. Cardiovascular
Diabetology 2012 11:107.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
